According to the latest Lux Research report1, many of the high profile biotech start-ups that went public through stock market launch or IPO (Initial Public Offering) have performed rather poorly. Of the nine companies it examined, for seven, the stock price change has been between 51.3 and 96.9% lower since IPO launch. So what is the underlying reason for this?… Login to continue

Login or sign up